# ReCode Therapeutics

> ReCode Therapeutics is a clinical-stage genetic medicines company using its Selective Organ Targeting (SORT) lipid nanoparticle platform to deliver mRNA and gene-correction therapies beyond the liver. Its lead programs target cystic fibrosis and primary ciliary dyskinesia - rare respiratory diseases where existing modulators leave many patients without options.

- **Founded:** 2015
- **Headquarters:** Menlo Park, California, United States
- **Founders:** Daniel J. Siegwart (Co-founder, Scientific Advisory Board Chair), David J. Lockhart (Co-founder (via TranscripTx merger), Former CEO), Arthur Johnson (Co-founder), Philip Thomas (Co-founder), Michael Torres (Co-founder), Leon Chen (Co-founder (TranscripTx)), Peter Thompson (Co-founder (TranscripTx))
- **Team size:** ~61 employees
- **Products:** SORT LNP Platform, RCT2100, RCT1100, CF gene correction program
- **Notable:** FDA Orphan Drug Designation for RCT2100 in cystic fibrosis, First patient dosed in Phase 1b clinical study of RCT2100, Total funding raised exceeds $345 million

## Products & services

- **SORT LNP Platform** — Selective Organ Targeting lipid nanoparticle delivery system that enables targeted delivery of mRNA, gene-editing and gene-correction payloads to specific organs and cell types outside the liver.
- **RCT2100** — Inhaled CFTR mRNA candidate for cystic fibrosis patients with mutations that do not respond to CFTR modulators. Currently in Phase 1 and Phase 1b clinical studies.
- **RCT1100** — Inhaled mRNA therapy candidate for primary ciliary dyskinesia, delivering DNAI1 mRNA to airway cells.
- **CF gene correction program** — Partnered with Intellia Therapeutics and supported by the Cystic Fibrosis Foundation; CRISPR-based gene correction delivered to airway cells via SORT LNP.

## Achievements

- FDA Orphan Drug Designation for RCT2100 in cystic fibrosis
- First patient dosed in Phase 1b clinical study of RCT2100
- Total funding raised exceeds $345 million
- Recognized as a Best Place to Work in BioPharma
- Built one of the few clinical-stage LNP delivery platforms capable of reaching beyond the liver

## Latest updates

- **2025-09** — Announced $29M+ in additional financing and corporate update on pipeline progress.
- **2024-10** — Presented preclinical CF program data at the North American Cystic Fibrosis Conference in Boston.
- **2024** — Dosed first cystic fibrosis patient in Phase 1b clinical study of RCT2100.
- **2023-09** — Closed $50M Series B extension.

## Links

- Website: https://recodetx.com
- LinkedIn: https://www.linkedin.com/company/recode-therapeutics

---

Profile page: https://yespress.io/recode-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-05-18